Michael Scott Kramer is a notable inventor based in Harleysville, PA (US). He has made significant contributions to the field of medical treatments, particularly in the area of fibrosis. With a total of 2 patents, Kramer's work focuses on innovative methods for diagnosing and treating fibrosis-related disorders.

Latest Patents

Kramer's latest patents include groundbreaking methods for treating fibrosis using C reactive protein (CRP) antagonists. This application provides methods for determining a patient's risk for developing fibrosis or a fibrosis-related disorder. By measuring concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) from a biological sample, the SAP-to-CRP ratio can be established. This ratio is then compared with reference ratios to assess a patient's risk for developing a fibrosis-related disorder. Additionally, the diagnostic methods can determine the severity of fibrosis in afflicted patients. Furthermore, Kramer has developed methods for treating patients with fibrosis-related disorders, suggesting that those with a lower SAP-to-CRP ratio may benefit from treatment with an SAP agonist and/or CRP antagonist. His work also explores the R131/H131 polymorphism of FcγRIIA as a risk factor for developing fibrosis.

Career Highlights

Kramer is currently associated with Promedior, Inc., where he continues to advance his research and innovations in the medical field. His work has the potential to significantly impact the treatment of patients suffering from fibrosis and related conditions.

Collaborations

Kramer collaborates with esteemed colleagues, including David Paul Hesson and Mark L. Lupher, Jr. Their combined expertise enhances the research and development of effective treatments for fibrosis.

Conclusion

Michael Scott Kramer is a dedicated inventor whose work in fibrosis treatment showcases his commitment to improving patient outcomes. His innovative methods and collaborations position him as a key figure in the medical research community.